Stock Events

Stock Events

LENZ Therapeutics 

$9.67
3
+$0.32+3.42% Thursday 19:58

Statistics

Day High
10.08
Day Low
9.15
52W High
50.4
52W Low
8.25
Volume
698,047
Avg. Volume
1,107,162
Mkt Cap
302.57M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Mar 24
$7.21
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

13MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.16
-0.9
-0.64
-0.38
Expected EPS
-1.007662
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-99.54MNet Income

Analyst Ratings

$43.00Average Price Target
The highest estimate is 67.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LENZ. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is a leader in the development of gene-based therapies, directly competing with Graphite Bio's gene editing technologies.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space, making it a direct competitor to Graphite Bio in developing gene-edited therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology space, competing with Graphite Bio in the gene editing therapy market.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor to Graphite Bio in the precision genetic medicine field.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, competing with Graphite Bio in the development of genetic treatments.
Voyager Therapeutics
VYGR
Mkt Cap259.04M
Voyager Therapeutics specializes in gene therapy, particularly for neurological diseases, competing with Graphite Bio in the broader gene therapy market.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics operates in the field of genetic disorders, competing with Graphite Bio in the development of treatments for genetic diseases.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, making it a competitor in the gene therapy market where Graphite Bio operates.

About

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Show more...
CEO
Mr. Evert B. Schimmelpennink
Employees
6
Country
US
ISIN
US52635N1037

Listings

XNAS
US
LENZ
BOATS
BOATS
LENZ.BOATS

0 Comments

Share your thoughts

FAQ

What is LENZ Therapeutics stock price today?▼
The current price of LENZ is $9.67 USD — it has increased by +3.42% in the past 24 hours. Watch LENZ Therapeutics stock price performance more closely on the chart.
What is LENZ Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange LENZ Therapeutics stocks are traded under the ticker LENZ.
Is LENZ Therapeutics stock price growing?▼
LENZ stock has risen by +15.12% compared to the previous week, the month change is a -25.39% fall, over the last year LENZ Therapeutics has showed a -54.34% decrease.
What is LENZ Therapeutics market cap?▼
Today LENZ Therapeutics has the market capitalization of 302.57M
When is the next LENZ Therapeutics earnings date?▼
LENZ Therapeutics is going to release the next earnings report on May 13, 2026.
What were LENZ Therapeutics earnings last quarter?▼
LENZ earnings for the last quarter are -1.16 USD per share, whereas the estimation was -0.91 USD resulting in a -27.71% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is LENZ Therapeutics revenue for the last year?▼
LENZ Therapeutics revenue for the last year amounts to 0 USD.
What is LENZ Therapeutics net income for the last year?▼
LENZ net income for the last year is -99.54M USD.
Does LENZ Therapeutics pay dividends?▼
Yes, LENZ dividends are paid en. The last dividend per share was 7.21 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does LENZ Therapeutics have?▼
As of April 04, 2026, the company has 6 employees.
In which sector is LENZ Therapeutics located?▼
LENZ Therapeutics operates in the Health Care sector.
When did LENZ Therapeutics complete a stock split?▼
The last stock split for LENZ Therapeutics was on March 22, 2024 with a ratio of 1:7.
Where is LENZ Therapeutics headquartered?▼
LENZ Therapeutics is headquartered in Solana Beach, US.